Alx Oncology Holdings Inc (NASDAQ: ALXO)’s stock price has increased by 12.41 compared to its previous closing price of 12.89. However, the company has seen a 17.42% increase in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-11 that ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.
Is It Worth Investing in Alx Oncology Holdings Inc (NASDAQ: ALXO) Right Now?
The 36-month beta value for ALXO is at 1.49. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ALXO is 27.36M, and currently, shorts hold a 11.41% of that float. The average trading volume for ALXO on April 17, 2024 was 401.38K shares.
ALXO’s Market Performance
The stock of Alx Oncology Holdings Inc (ALXO) has seen a 17.42% increase in the past week, with a 28.23% rise in the past month, and a 3.72% gain in the past quarter. The volatility ratio for the week is 10.26%, and the volatility levels for the past 30 days are at 7.49% for ALXO. The simple moving average for the past 20 days is 22.76% for ALXO’s stock, with a 49.16% simple moving average for the past 200 days.
Analysts’ Opinion of ALXO
Many brokerage firms have already submitted their reports for ALXO stocks, with Stifel repeating the rating for ALXO by listing it as a “Hold.” The predicted price for ALXO in the upcoming period, according to Stifel is $14 based on the research report published on March 08, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see ALXO reach a price target of $18, previously predicting the price at $8. The rating they have provided for ALXO stocks is “Buy” according to the report published on December 08th, 2023.
Jefferies gave a rating of “Hold” to ALXO, setting the target price at $25 in the report published on December 22nd of the previous year.
ALXO Trading at 6.66% from the 50-Day Moving Average
After a stumble in the market that brought ALXO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.82% of loss for the given period.
Volatility was left at 7.49%, however, over the last 30 days, the volatility rate increased by 10.26%, as shares surge +32.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.43% lower at present.
During the last 5 trading sessions, ALXO rose by +17.42%, which changed the moving average for the period of 200-days by +97.68% in comparison to the 20-day moving average, which settled at $11.98. In addition, Alx Oncology Holdings Inc saw -2.69% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALXO starting from Pons Jaume, who sale 20,000 shares at the price of $11.15 back on Apr 04 ’24. After this action, Pons Jaume now owns 628,359 shares of Alx Oncology Holdings Inc, valued at $223,036 using the latest closing price.
Lettmann Jason, the CHIEF EXECUTIVE OFFICER of Alx Oncology Holdings Inc, purchase 4,400 shares at $11.31 during a trade that took place back on Mar 14 ’24, which means that Lettmann Jason is holding 171,620 shares at $49,771 based on the most recent closing price.
Stock Fundamentals for ALXO
The total capital return value is set at -0.82. Equity return is now at value -70.97, with -58.58 for asset returns.
Based on Alx Oncology Holdings Inc (ALXO), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -11.63. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -217.47.
Currently, EBITDA for the company is -169.44 million with net debt to EBITDA at 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.24.
Conclusion
In conclusion, Alx Oncology Holdings Inc (ALXO) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
